Benign Prostatic Hyperplasia Market to Reach USD 8.3 Billion by 2034, Driven by Rising Treatment Demand - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - Makers of BPH surgical devices and implants are working against a staggered European regulatory clock, with higher-risk implantable devices given until the end of 2027 and medium- and lower-risk devices until the end of 2028 to complete conformity assessment, a timeline that is keeping compliance and clinical-evidence spending elevated across device portfolios even as the sell-off restriction on already-compliant products has been withdrawn. Against that backdrop, the benign prostatic hyperplasia market was valued at USD 4.5 billion in 2025 and is projected to reach USD 8.3 billion by 2034, growing at a CAGR of 7.00% between 2026 and 2034, according to a new report from Strategic Revenue Insights Inc. The findings are led by lead analyst Thomas Müller, and the report is built on primary interviews with hospitals, urology clinics, ambulatory surgical centers, and home care providers, combined with secondary research spanning Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

Key Takeaways

• The benign prostatic hyperplasia market is valued at USD 4.5 billion in 2025 and is forecast to reach USD 8.3 billion by 2034, at a CAGR of 7.00%.
• Pharmaceuticals hold the largest product segment, while Minimally Invasive Surgical Therapies are the fastest-growing treatment segment.
• Digital health tools, including telemedicine and remote monitoring, are enhancing patient engagement and treatment outcomes.
• North America leads the market, while Asia Pacific is experiencing the fastest growth.
• Boston Scientific, Teleflex, and Olympus are among the leading providers shaping the competitive landscape.

Full report access: https://www.strategicrevenueinsights.com/industry/benign-prostatic-hyperplasia-market

An Aging Male Population and a Shift Toward Minimally Invasive Care Are Driving Growth

The most fundamental driver behind this market is demographic. BPH affects approximately 50% of men aged 51 to 60 and up to 90% of men over 80, according to the National Institutes of Health, meaning the condition's prevalence rises sharply as the global male population ages. That demographic reality is compounded by rising awareness and diagnosis rates, supported by public health initiatives and educational campaigns that are encouraging earlier diagnosis and treatment, along with government efforts to improve urological care access and healthcare infrastructure.

Treatment innovation is reinforcing this demand. The market is shifting toward minimally invasive surgical therapies, including laser therapies and prostatic urethral lift and water vapor therapy, which offer reduced recovery times and fewer complications compared with traditional surgical resection. This is driving investment in advanced surgical devices and implants, while combination drug therapy, pairing 5-alpha reductase inhibitors with alpha blockers, is gaining traction as a comprehensive approach to symptom management that supports the broader move toward personalized medicine.

A third factor is the accelerating integration of digital health tools. Telemedicine and remote monitoring are changing how BPH patients are managed, giving healthcare providers more efficient and accessible ways to deliver care while improving outcomes and reducing costs. The report also notes that e-commerce platforms are expanding how pharmaceuticals and medical devices reach patients, broadening market accessibility alongside these clinical care changes.

Market Segmentation

By treatment type, Alpha Blockers remain widely used for their effectiveness in relaxing prostate and bladder neck muscles, while Minimally Invasive Surgical Therapies, including laser therapies and prostatic urethral lift, are the fastest-growing category as patients and providers favor reduced recovery times; Combination Drug Therapy, 5-Alpha Reductase Inhibitors, and Transurethral Resection continue to serve patients across different symptom profiles.

By product, Pharmaceuticals hold the largest share, driven by demand for effective drug therapies and novel combination formulations, while Surgical Devices & Implants are gaining popularity alongside rising demand for minimally invasive procedures; Diagnostic Equipment continues to advance as companies apply imaging expertise to improve BPH diagnosis.

By severity, mild cases are typically managed through lifestyle changes and medication, while the growing share of moderate and severe cases is driving demand for more advanced treatment options, including minimally invasive surgical therapies and combination drug therapy tailored to patient-specific needs.

By end use, Hospitals hold the largest share given their advanced infrastructure and access to specialized care, while Urology Clinics are gaining popularity for offering specialized, personalized treatment; Ambulatory Surgical Centers are becoming a preferred choice for minimally invasive procedures, and Home Care is emerging as telemedicine and digital health adoption make at-home condition management more feasible.

Regional Outlook

North America is the largest regional market, supported by advanced healthcare infrastructure and high awareness, while Asia Pacific is experiencing the fastest growth, driven by rising BPH prevalence and increasing healthcare investment. Europe, Latin America, and the Middle East & Africa round out the report's regional coverage, each contributing to overall market expansion as diagnosis rates and treatment access continue to improve.

Competitive Landscape

Boston Scientific is known for its advanced surgical devices and implants, backed by a strong commitment to research and development aimed at enhancing its product offerings. Teleflex is recognized for its minimally invasive surgical therapies and is actively expanding its presence in emerging markets. Olympus leverages its expertise in imaging technology to develop advanced diagnostic equipment for BPH, positioning it as a leader in the diagnostic segment of the market.

Market Restraints

The market's growth is tempered by the high cost of treatment, which can limit access to care, particularly where reimbursement policies remain limited. Stringent regulatory approval processes for new therapies and medical devices add a further constraint, as they can delay market entry and raise development costs for companies bringing new treatments to market.

Related Reports

https://www.strategicrevenueinsights.com/industry/food-waste-management-market

https://www.strategicrevenueinsights.com/industry/fruit-and-vegetable-juice-market

https://www.strategicrevenueinsights.com/industry/functional-food-probiotics-market

https://www.strategicrevenueinsights.com/industry/functional-foods-nutraceuticals-market

https://www.strategicrevenueinsights.com/industry/oral-clinical-nutritional-supplement-market

Frequently Asked Questions

How big is the benign prostatic hyperplasia market?

The market was valued at USD 4.5 billion in 2025 and is projected to reach USD 8.3 billion by 2034, growing at a CAGR of 7.00%.

What is driving growth in the benign prostatic hyperplasia market?

Growth is driven by the increasing prevalence of BPH among the aging male population and advancements in treatment options.

Which region leads the benign prostatic hyperplasia market?

North America is the largest regional market, while Asia Pacific is experiencing the fastest growth.

Who are the leading companies in the benign prostatic hyperplasia market?

Leading companies named in the report include Boston Scientific, Teleflex, and Olympus.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases